By Lisa Rapaport

(Reuters Health) - The proportion of U.S. adults who get recommended colon cancer screenings has never been as high as doctors would like, but a new study suggests that it’s much lower than expected in some pockets of the country.

By Will Boggs MD

NEW YORK (Reuters Health) - The checkpoint inhibitors anti-PD-1 and anti-PD-L1 are rarely associated with serious organ-specific immune-related adverse events, according to a new systematic review and meta-analysis.

Following the dual-keynote presentations given by Ron Kline, MD, FAAP, and Lee N Newcomer, MD, MHA, a lively roundtable discussion took place on the NCCN stage regarding critical current and emerging issues in the delivery of cancer care in value-based care models.
Major advances in the biology and treatment of patients with CLL have prompted the International Workshop on CLL to evaluate and revise the criteria for their consensus guideline in this disease setting.
The second presentation of the NCCN Annual Conference Keynote session was given by Lee N Newcomer, MD, MHA, a leading voice in the payer community, who spoke on cancer care delivery from the managed care perspective.
In the first presentation NCCN Annual Conference Keynote session, Ron Kline, MD, FAAP, gave an overview of the OCM and an unofficial preview of the preliminary data CMMI has accrued from OCM practices within the first 6 months of implementation.
Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a presentation at the SGO 2018 Annual Meeting on Women’s Cancer.
A featured poster session at the SGO 2018 Annual Meeting on Women’s Cancer detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer.
Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.